|
Q3 2023
|
1 |
29,226 |
TXG
|
13F-HR
|
11/13/2023 |
000110465923117289 |
|
Q2 2023
|
1 |
39,564 |
TXG
|
13F-HR
|
8/11/2023 |
000110465923090053 |
|
Q1 2023
|
1 |
39,528 |
TXG
|
13F-HR
|
5/12/2023 |
000110465923059496 |
|
Q4 2022
|
1 |
49,504 |
TXG
|
13F-HR
|
2/13/2023 |
000110465923019771 |
|
Q3 2022
|
1 |
49,940 |
TXG
|
13F-HR
|
11/14/2022 |
000110465922117990 |
|
Q2 2022
|
1 |
79,347 |
TXG
|
13F-HR
|
8/12/2022 |
000110465922089756 |
|
Q1 2022
|
1 |
133,391 |
TXG
|
13F-HR
|
5/13/2022 |
000110465922059930 |
|
Q4 2021
|
2 |
262,931 |
TXG, EPZM
|
13F-HR
|
2/11/2022 |
000110465922020348 |
|
Q3 2021
|
4 |
281,405 |
TXG, NVAX, XLRN, EPZM
|
13F-HR
|
11/12/2021 |
000110465921137696 |
|
Q2 2021
|
4 |
371,748 |
TXG, NVAX, EPZM, XLRN
|
13F-HR
|
8/16/2021 |
000110465921105285 |
|
Q1 2021
|
4 |
435,036 |
TXG, NVAX, EPZM, XLRN
|
13F-HR
|
5/17/2021 |
000110465921067101 |
|
Q4 2020
|
4 |
378,743 |
TXG, EPZM, NVAX, XLRN
|
13F-HR
|
2/16/2021 |
000110465921023076 |
|
Q3 2020
|
4 |
459,571 |
TXG, EPZM, NVAX, XLRN
|
13F-HR
|
11/13/2020 |
000110465920124779 |
|
Q2 2020
|
3 |
508,684 |
TXG, EPZM, XLRN
|
13F-HR
|
8/13/2020 |
000110465920094439 |
|
Q1 2020
|
6 |
428,291 |
TXG, EPZM, INSM, Aerie Pharmaceuticals, Inc.
|
13F-HR
|
5/14/2020 |
000110465920061243 |
|
Q4 2019
|
5 |
607,331 |
TXG, Aerie Pharmaceuticals, Inc., INSM, EPZM
|
13F-HR
|
2/5/2020 |
000110465920010864 |
|
Q3 2019
|
7 |
473,022 |
TXG, AIMT, Aerie Pharmaceuticals, Inc., INSM
|
13F-HR
|
11/13/2019 |
000110465919062958 |
|
Q2 2019
|
7 |
177,867 |
AIMT, Aerie Pharmaceuticals, Inc., INSM, EPZM
|
13F-HR
|
8/13/2019 |
000114420419039327 |
|
Q1 2019
|
8 |
221,488 |
Aerie Pharmaceuticals, Inc., AIMT, INSM, ALDR
|
13F-HR
|
5/14/2019 |
000114420419025829 |
|
Q4 2018
|
10 |
188,692 |
AIMT, Aerie Pharmaceuticals, Inc., ALDR, INSM
|
13F-HR
|
2/13/2019 |
000114420419007300 |
|
Q3 2018
|
10 |
270,204 |
Aerie Pharmaceuticals, Inc., AIMT, ALDR, INSM
|
13F-HR
|
11/13/2018 |
000114420418059266 |
|
Q2 2018
|
10 |
283,859 |
Aerie Pharmaceuticals, Inc., AIMT, ALDR, INSM
|
13F-HR
|
8/14/2018 |
000114420418044623 |
|
Q1 2018
|
11 |
300,625 |
AIMT, Aerie Pharmaceuticals, Inc., EPZM, INSM
|
13F-HR
|
5/15/2018 |
000114420418028462 |
|
Q4 2017
|
11 |
286,236 |
AIMT, Aerie Pharmaceuticals, Inc., EPZM, INSM
|
13F-HR
|
2/13/2018 |
000114420418007688 |
|
Q3 2017
|
12 |
246,705 |
AIMT, Aerie Pharmaceuticals, Inc., EPZM, ALDR
|
13F-HR
|
11/13/2017 |
000114420417058212 |
|
Q2 2017
|
13 |
218,256 |
Aerie Pharmaceuticals, Inc., AIMT, EPZM, ALDR
|
13F-HR
|
8/14/2017 |
000114420417042938 |
|
Q1 2017
|
13 |
233,108 |
AIMT, Aerie Pharmaceuticals, Inc., EPZM, ALDR
|
13F-HR
|
5/12/2017 |
000114420417026668 |
|
Q4 2016
|
9 |
199,266 |
AIMT, Aerie Pharmaceuticals, Inc., ALDR, EPZM
|
13F-HR
|
2/10/2017 |
000114420417007450 |
|
Q3 2016
|
10 |
209,419 |
Aerie Pharmaceuticals, Inc., AIMT, ALDR, UAM
|
13F-HR
|
11/14/2016 |
000114420416133782 |
|
Q2 2016
|
15 |
146,280 |
AIMT, UAM, Aerie Pharmaceuticals, Inc., ALDR
|
13F-HR
|
8/12/2016 |
000114420416118725 |
|
Q1 2016
|
20 |
204,330 |
AIMT, UAM, KDNY, EPZM
|
13F-HR
|
5/6/2016 |
000114420416099539 |
|
Q4 2015
|
24 |
298,243 |
AIMT, KDNY, ADAP, UAM
|
13F-HR
|
2/12/2016 |
000114420416081039 |
|
Q3 2015
|
29 |
329,345 |
AIMT, KDNY, LRMR, ADAP
|
13F-HR
|
11/13/2015 |
000114420415065115 |
|
Q2 2015
|
22 |
284,975 |
KDNY, ADAP, UAM, LRMR
|
13F-HR
|
8/14/2015 |
000114420415049188 |
|
Q1 2015
|
17 |
168,778 |
LRMR, Orexigen Therapeutics, Inc., EPZM, ASPX
|
13F-HR
|
5/5/2015 |
000114420415027507 |
|
Q4 2014
|
23 |
146,039 |
UAM, Orexigen Therapeutics, Inc., LRMR, ASPX
|
13F-HR
|
2/11/2015 |
000114420415008023 |